VERONA PHARMA LIMITED

• ⚠

  Confirmation statement overdue

  Due 2026-03-10.

• ◆

  11 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Figures converted to GBP from USD at 0.748 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  +47.1%

  £203,163,639 → £298,839,052

• Net assets

  —

  Not reported

• Employees

  +181%

  58 → 163

• Operating profit

  -92.6%

  -£51,351,574 → -£98,900,351

• Profit before tax

  -140.1%

  -£54,537,639 → -£130,956,119

• Wages

  +153.7%

  £11,263,362 → £28,578,157

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. VERONA PHARMA LIMITED 2025-10-22 → present
2. VERONA PHARMA PLC. 2006-09-18 → 2025-10-22
3. ISIS RESOURCES PLC 2005-02-24 → 2006-09-18

Accounting basis

FRS 101

Reporting scope

Consolidated group

Auditor

Ernst & Young Chartered Accountants

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“We have incurred recurring losses and negative cash flows from operations since inception and have accumulated loss of $600.2 million as of December 31, 2024. We expect that our cash and cash equivalents, together with additional funding expected to become available under the 2024 Term Loan and RIPSA, will enable us to fund our planned operating expenses and capital expenditure requirements, including the commercial launch of Ohtuvayre for at least the next 12 months from the date of approval of these finance statements.”

Group structure

1. VERONA PHARMA LIMITED · parent
   1. Verona Pharma, Inc. 100% · Delaware, USA · Development and commercialization of innovative therapeutics

Significant events

• “On June 26, 2024, the U.S. Food and Drug Administration ("FDA") approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") in adult patients and we launched Ohtuvayre in the United States.”
• “Cash and cash equivalents at December 31, 2024 increased to $399.8 million from $271.8 million at December 31, 2023 primarily due to cash inflows from financing activities due to a loan agreement and a revenue interest purchase and sale agreement entered into in 2024.”
• “In May 2024, the Group continued to strengthened its financial position through term loan and royalty interest purchase and sale facilities which replaced the prior outstanding term debt.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

0

last 24 months

Officers appointed

3

last 12 months

Officers resigned

11

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.